mitiglinide mitiglinide mitiglinide (inn, trade name glufast) is a drug for the treatment of type 2 diabetes. mitiglinideclinical datatrade namesglufastahfs/drugs.cominternational drug namesroutes ofadministrationby mouth (tablets)atc codea10bx08 (who) identifiers iupac name (−)-(2s,3a,7a-cis)-α-benzylhexahydro-γ-oxo-2-isoindolinebutyric acid cas number145375-43-5 npubchem cid121891drugbankdb01252 ychemspider108739 yuniid86i0xlb13keggd01854 ychemblchembl471498 ycomptox dashboard (epa)dtxsid4048303 chemical and physical dataformulac19h25no3molar mass315.413 g·mol−13d model (jsmol)interactive image smiles o=c(o)(cc1ccccc1)cc(=o)n3c2cccc2c3 inchi inchi=1s/c19h25no3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17h,4-5,8-13h2,(h,22,23)/t15-,16+,17-/m0/s1 ykey:wpgghfddfphpob-bbwfwoeesa-n y ny (what is this?) (verify) mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in japan by kissei and takeda. the north america rights to mitiglinide are held by elixir pharmaceuticals. mitiglinide has not yet gained fda approval. pharmacology mitiglinide is thought to stimulate insulin secretion by closing the atp-sensitive potassium katp channels in pancreatic β cells. dosage mitiglinide is delivered in tablet form.